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Abstract
Background: Providing population-based data on awareness, attitude and practice of drug and stimulant use 
has policy implications. A national study was conducted among Iranian general population to explore life time 
prevalence, awareness and attitudes toward opioids and stimulant use.
Methods: We recruited subjects from 5 provinces with heterogenic pattern of drug use. Participants were 
selected using stratified multistage cluster sampling. Data were collected using a validated self-administered 
questionnaire. Logistic regression model was applied to identify the variables that are associated with drug and 
stimulant use. 
Results: In total 2065 respondents including 1155 men (33.96 ± 10.40 years old) and 910 women (35.45 ± 
12.21 years old) were recruited. Two-third of respondents had good awareness about adverse effects of opioid 
use. Corresponding figure in terms of stimulants was 81.4%. Almost 95% of participants reported a negative 
attitude towards either opioid or stimulant use. The lifetime prevalence of opioid use and stimulant use were 
12.9% (men: 21.5%, women: 4.0%) and 7.3% (men: 9.6%, women: 4.9%), respectively. Gender (adjusted odds 
ratio [AOR]M/W =  6.92; 95% CI: 2.92, 16.42), education (AORundergraduate/diploma or less = 0.49; 95% CI: 0.26, 0.90), and 
marital status (AORothers/single = 2.13; 95% CI: 1.36, 3.33) were significantly related with opioid use. With respect 
to stimulant use, age was negatively associated with the outcome (AOR60+/20-29 years = 0.08: 95% CI; 0.01, 0.98) and 
men were 2 times more likely than women to use stimulants (ORM/W=2.15: 95% CI: 0.83, 5.56). In addition, 
marital status (AOROthers/singles = 3.45; 95% CI: 1.09, 10.93), and awareness (AORWeak and moderate/good = 0.40; 95% CI: 
0.25, 0.61) were independently correlated with stimulants use. 
Conclusion: While the attitude of Iranian adults toward opioid and stimulant use was negative, their awareness 
was not that adequate to prevent the drug use. Men and those with lower socio-economic status (SES) should be 
the focus of health promotion programs regarding opioid use. However, regarding stimulants use, promotion 
programs should target younger age groups and those with higher SES status.
Keyword: Cognition, Attitude, Prevalence, Opioid Related Disorders, Amphetamines
Copyright: © 2019 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Citation: Mohebbi E, Haghdoost AA, Noroozi A, et al. Awareness and attitude towards opioid and stimulant use 
and lifetime prevalence of the drugs: a study of 5 large cities of Iran. Int J Health Policy Manag. 2019;8(4):222–
232. doi:10.15171/ijhpm.2018.128
*Correspondence to:
Mohammad Reza Baneshi  
Email: rbaneshi2@gmail.com
Article History:
Received: 26 November 2017
Accepted: 15 December 2018
ePublished: 31 December 2018
Original Article
Full list of authors’ affiliations is available at the end of the article.
http://ijhpm.com
Int J Health Policy Manag 2019, 8(4), 222–232 doi 10.15171/ijhpm.2018.128
Implications for policy makers
• The life time prevalence of opioids and stimulants were 12.9% (men: 21.5%, women: 4.0%) and 7.3% (men: 9.6%, women: 4.9%) respectively. 
• In terms of opioid use, health promotion programs should target men and populations with lower socio-economic status (SES) status.
• Regarding stimulants use, promotion programs should target the younger age groups and those with high SES status.
Implications for the public
The life time prevalence of opioid and stimulants use among men was 5 and 2 times higher than that of women. Although most Iranians were aware 
of adverse effects of opioid and stimulants use, the life time prevalence of these outcomes were high. Appropriate health promotion programs should 
be designed to decrease use of these drugs.
Key Messages 
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Introduction
Illicit drug use poses striking challenges to health systems 
worldwide. In 2016, 275 million of world population aged 
15-64 used an illicit drug, which was accounted for 5.6% 
of the population.1 In addition to that, global mortality 
and morbidity attributed to illicit drug use, which mostly 
happened in Eastern Europe and Central Asia, is substantial 
(37 926 000 million disability-adjusted life years [DALYs]). 
Opioid dependence was the largest contributor of years 
life lost (YLLs) to premature mortality for illicit drug use 
disorders.2 In 2010, global burden of diseases estimated 804.5 
and 227 for DALYs and 351.8 and 24.8 for YLLs in Iranian 
men and women, respectively.3
Several studies confirmed that increase in drug use 
disorders are associated with increase in number of shattered 
families, as well as crime, violence and insecurity, and health 
related problems including HIV and hepatitis C (via injecting 
drugs).4,5 It also affects economic costs, especially in low- and 
middle-income countries (LMICs).6
Iran is an Islamic middle-income country with a population 
of more than 80 million, of whom more than 70% live in 
urban settings.7 Except for medical purposes, using opioids 
and stimulants are illegal in Iran. Despite negative attitudes 
toward drug use among older Iranians, it has been less 
stigmatized and even partly prestigious among youths.8-10 
This could make drug-related issues uncontrollable especially 
among younger adults and women.6 According to the national 
household survey, last year prevalence of any illicit drug use 
disorder except alcohol was 2.44% (1.56% drug dependence), 
accounting for approximately 1.12 million Iranians (15-
64 years). Amongst the illicit drugs, opioids were the most 
prevalent one with prevalence of 2.23% (95% CI; 1.83%, 
2.62%), following by cannabis (0.56%) and amphetamine-
type stimulants (ATS) (0.39%).8 Moreover, prevalence of ATS 
used is very high in specific sub-population, for instance 
73.9% among transit driver and 46.5%.11,12 
Opioids are the most popular drug of use in Iran drug 
scene and have been used more than 5 centuries, partly 
due to long and porous border with Afghanistan, the main 
producer of illicit opioids in the world.2,13 In contrast, ATS 
are almost the new brand drugs in Iran’s market (since 
2005),14 firstly, imported from southeastern border. While 
ATS use is associated with many mental (insomnia, anxiety, 
and psychosis) and physical health complications (increased 
body temperature, and increased rapid heart rate), knowledge 
about its side effects is low.15-17 Besides, international sanctions 
negatively affect economic growth which might result in 
social harms including illicit drug use.18
There are several references to opium – “Tariak” in Persian 
– in Iranian medieval and classic poems where opium was 
considered as an “antidote” to treat diseases. Furthermore, 
opium has been used to treat pain, cough and diarrhea in 
Iranian traditional medicine.19 Nowadays, patients adhere to 
the faulty superstition about opium and sometimes initiating 
to use it by disease development without any awareness 
about the side effects and addictive properties.17,20 Available 
evidences on awareness and attitude toward opium are slim 
and the focuses of majority of such studies are on nursing and 
medical students, or high school students.21-23 
Although ATS are the new brand drug in Iran illicit drug 
markets, a number of studies – including Persian and English 
and gray literature – evaluated amphetamine and ecstasy 
use awareness and attitude. Nonetheless, results of the most 
recent knowledge, attitude and practice study on Iranian 
youths (4868 participants aged 15-29 years) showed that 42% 
of participants had low knowledge, and about one-third of 
them had positive attitudes towards amphetamine use.24 
As mentioned above majority of studies were concentrated 
on specific groups. However, we believe that general population 
should be the main target group for health education and 
promotion strategies. Therefore, a large study was conducted 
to explore life time prevalence of opioid and stimulant use, as 
well as awareness and attitudes toward opioid and stimulant 
use among Iranian adults.
Methods
Participants and Sampling Design
In 2013, Iranian National Network Scale Up (NSU) study was 
designed to estimate the prevalence of opioids and to stratify 
the country into low, intermediate, and high-risk zones. At the 
first step, results of that study were used to select 5 provinces: 
West Azerbaijan and Markazi from low risk stratum, Tehran 
and Khorasan-e-Razavi from moderate risk stratum, and 
Kerman from high risk stratum. Data are collected in capitals. 
Each city was stratified into low, middle and high socio-
economic zones. 
A street-based consecutive sampling was used to recruit the 
respondents at different times and locations. The inclusion 
criteria were consent verbally obtained, over 18 years old, and 
able to reading and writing in Persian.
Sample size calculation was based on information obtained 
from evaluating drug abuse awareness among Afghans 
(88.6%).25 We assumed that proportion of awareness about 
drug use 0.9 and d = 0.03 in both sexes (
2
2
(1 )z p pn
d
−
= ). This 
suggests a sample size of 400 for each province.
Designing Instrument
A self-administered questionnaire was designed considering 
socio-cultural context of Iran. The questionnaire was 
developed in 4 phases; (1) literature review, (2) expert panel 
review, (3) focus-group testing and evaluation, and (4) and 
reliability and validity assessment.
An extended literature review was conducted to ascertain 
common awareness and attitude statements related to opioid 
and stimulant use, and to find available instruments. We found 
various studies and reports.26-33 Reviewing the questionnaires, 
a question pool inquiring awareness, attitude and behavior 
on opioid and stimulants use was developed and discussed in 
expert panel reviews.
Expert Panel Review
Experts from Iranian National Center for Addiction Studies 
(INCAS) [Tehran, Iran], Tehran University of Medical 
Sciences (TUMS) [Tehran, Iran], and Neuroscience Research 
Center, Institute of Neuropharmacology [Kerman, Iran] 
reviewed the questionnaires and their invaluable feedbacks 
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were gathered.
Focus Group Discussion 
We conducted 2 focus group discussions (FGDs) to explore 
attitudes and opinions of youth population with respect 
to common type of drugs used among Iranian adults. A 
convenient sample of university students (n = 15) were 
selected from Kerman University of Medical Sciences 
(KUMS), Kerman, Iran. A letter was sent to these students 
explaining the purpose of the focus groups and assuring 
them that confidentiality would be maintained. In the first 
session, attitudes, perceived reasons and contexts of drug 
use initiation were discussed. In the second session the 
participants’ opinions regarding most prevalent type of drugs 
were explored and then participants were asked to talk about 
their awareness, attitude and experiences about drug use. The 
focus groups were facilitated by EM.
Designing of the Questionnaire
Based on lessons from FGD, 6 conceptual frameworks were 
drawn for awareness, attitude and life time prevalence of 
opium and stimulant use. Draft was revised several times 
according to the experts’ feedback so that the face validity of 
final version was approved by experts and consultants.
Assessment of Reliability and Validity 
To address the validity, we asked 34 medical doctors and nurses, 
who worked in medical centers, to fill the questionnaire. 
Cronbach α was calculated at 0.90 for awareness, 83% for 
attitude, and 87% for practice. 
For validity assessment, we asked 5 experts to describe 
the relevance degree of the questions (completely relevant, 
relatively relevant, relevant, and irrelevant). Content validity 
index (CVI) was estimated at about 0.8 which confirmed that 
validity of our questionnaire. 
Structure of Questionnaire 
In the first part of the questionnaire, using 20 questions with 
3 possible answers (correct, incorrect, and I do not know), 
awareness towards opioid and stimulants was assessed. Based 
on the number of correct replies, 3 categories were defined, 
weak (0 to 4), moderate (5 to 7), and good awareness (8 to 10). 
In the second section, which was consisted of 24 five-
point Likert scale questions, we measured the attitude. The 
questions were associated with attitude toward social, cultural, 
legalization, and religious contexts. An overall attitude was 
determined by aggregating all positive responses ranging 
from -24 to +24. Four categories were defined as: (I) strongly 
disagree [-24 to -13]; (II) disagree [-12 to -1]; (III) agree [+1 
to +12]; and (IV) strongly agree [+13 to +24]. 
The third part was devoted to practice of opioids and 
stimulants. We asked participants “Have you ever used opioid 
or stimulant, even one episode, during your life?” Opioids 
included opium, opium dross, condensed opium, heroin, 
crack-heroin, methadone, tramadol, and codeine. Stimulants 
included crystal methamphetamine, amphetamine, ecstasy, 
cocaine and Ritalin. Examples of drugs in each class and their 
common street names were provided in the questionnaire. In 
the last part of the questionnaire, demographic information 
was collected.
Data Collection Methods and Instrument
Data were collected by using the self-administered 
questionnaire along with guidance provided by interviewers in 
2015. At the first step, each city was stratified into low, middle 
and high socio-economic zones. A street-based consecutive 
sampling was used to recruit the respondents adopting time 
location sampling (TLS). We randomly selected some streets 
at different zones and asked data collectors to collect the 
data at different times. We asked them to recruit participants 
with different clothing and appearance to maximize the 
generalizability. Only pedestrians who walked alone were 
approached. 
After taking verbal consent, interviewees were asked to 
complete study questionnaire anonymously in the street 
corners. We matched the gender of data collector and 
interviewee. Interviewer took about 2-3 m distance from the 
respondent to avoid violation of the participants’ privacy. 
However, study participants’ questions were answered by the 
interviewers. An opaque envelope was provided for putting 
the questionnaire among completed questionnaires by other 
participants. 
Data Manipulation and Statistical Analysis
Data was cleaned and prepared based on the study protocol. 
Variables with more than 40% missing data were excluded. 
For the rest of variables, missing data were imputed applying 
multiple imputation by chained equations (MICE) method 
10 times. Linear, logistic, and multinomial regression models 
were used to impute missing data for linear, binary, and 
multinomial variables. 
Chi-square test and independent samples t test were 
used to determine the associations between qualitative 
and quantitative variables with opioid and stimulants 
use, respectively. P values less than 5% were considered 
as statistically significant. Logistic regression was applied 
to assess the association of demographic characteristics, 
awareness, and attitude with life time prevalence of opioid 
and stimulant use. Appropriate weights were applied, with 
respect to age and gender, to adjust for our sampling scheme. 
All variables were offered to the model. Using each imputed 
data set, a logistic regression model was fitted. Results of 10 
models were combined applying Rubin Rules. The variable 
with the highest P value was excluded. The process continued 
until all P values remained below 0.05. This iterative process 
guarantees exclusion of unimportant and correlated variables. 
We entered variables in the model that had missing data less 
than 40% and backward model was performed. Analyses were 
done using Stata v.12 (Stata Corporation College Station, TX, 
USA) and R software.
Results
The response rate was 86.0%. A total of 2065 individuals 
(1155 men and 910 women) filled the questionnaire. The 
mean age of men and women were 33.96 ± 10.40 and 35.45 
± 12.21 respectively. More than 70% of participants had an 
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undergraduate academic degree. Self-reported monthly 
income for almost 65% of participants was less than $334 
(exchange rate 1$: 4200 IRR) (Table 1).
Awareness
Opioid Use
Most of participants had good awareness about adverse 
effects of opioids on health (66.94%, 95% CI: 54.4, 79.5) and 
only 1.5% were not aware of adverse effects (95% CI: 0.0, 
1.5). About one-third of respondents had moderate level of 
awareness (31.5%, 95% CI: 20.4, 42.6).
Higher education was positively correlated with higher 
awareness. While 75% (95% CI: 69.5, 80.9) of those with 
graduate degree had good awareness, corresponding figure 
among those with high school or lower degree was 60.1% 
(95% CI: 38.1, 82.1). Marital status (P = .09) and employment 
status (P = .58) and age (P = .17) of respondents did not show 
association with their awareness but income (P < .0001) 
(Table 2).
Stimulant use
Almost 81.4% (95% CI: 76.7, 86.2) of participants had good 
awareness about adverse effects of stimulants on health and 
only 3% (95% CI: 1.2, 4.8) had weak awareness (Table 3). 
Table 1. Demographic and Socioeconomic Characteristics of Participants
Variable Men (n = 1155) Women (n = 910) P Total (N = 2065)
Age (y) 33.96 ± 10.40 35.45 ± 12.21 .004 34.80 ± 11.47
Marital status, No. (%)
<.0001
Never married 419 (36.3) 413 (45.4) 832 (40.3)
Married 644 (55.8) 392 (43.1) 1036 (50.2)
Others 92 (8.0) 105 (11.5) 197 (9.5)
Education, No. (%)
.395
High school or less 292 (25.3) 212 (23.3) 504 (24.4)
Undergraduate 813 (70.4) 650 (71.4) 1463 (70.8)
Graduate 50 (4.3) 48 (5.3) 98 (4.7)
Income (US$), No. (%)
<.0001
Less than 167 304 (26.3) 418 (45.9) 772 (35.0)
167-334 358 (31.0) 287 (31.5) 645 (31.2)
334-668 399 (34.5) 173 (19.0) 572 (27.7)
More than 668 94 (8.1) 32 (3.5) 126 (6.1)
Employment status, No. (%)
<.0001Unemployed 335 (29.0) 554 (60.9) 889 (43.1)
Employed 820 (71.0) 356 (39.1) 1176 (56.9)
Table 2. Awareness of Iranian Adults Towards Opioid Use, 2015
Variable
Knowledge (%, 95% CI)
Good Moderate Weak P
Opioids
Gender
Men 63.3 (49.0, 77.7) 35.0 (22.4, 47.6) 1.6 (0.0, 3.5)
<.0001
Women 70.8 (50.2, 91.2) 27.9 (9.6, 46.2) 1.4 (0.0, 3.6)
Education
Diploma or less 60.1 (38.1, 82.1) 37.6 (16.6, 58.6) 2.2 (0.0, 3.8)
<.0001Undergraduate 69.0 (61.7, 76.3) 29.6 (23.6, 35.6) 1.3 (0.0, 2.9)
Graduate 75.2 (69.5, 80.9) 24.5 (19.1, 30.5) -
Age
20-29 66.3 (54.4, 78.2) 32.6 (22.1, 43.0) 1.1 (0.0, 2.6)
.165
30-39 65.4 (55.6, 75.2) 32.9 (25.0, 40.8) 1.7 (0.0, 3.7)
40-49 67.2 (51.4, 82.9) 30.8 (16.7, 45.0) 2.0 (0.0, 4.7)
50-59 70.8 (52.1, 82.9) 26.8 (8.7, 45.0) 2.4 (0.0, 4.6)
More than 60 69.9 (48.0, 91.8) 30.0 (8.2, 52.0) -
Income
Less than 167 60.8 (42.0, 79.6) 37.0 (19.6, 54.3) 2.2 (0.0, 3.9)
<.0001
167-334 68.3 (60.5, 76.2) 30.0 (24.2, 35.9) 1.6 (0.0, 3.9)
334-668 74.2 (64.3, 84.0) 25.4 (16.1, 34.8) 0.3 (0.0, 1.1)
More than 668 68.7 (63.9, 73.5) 30.0 (24.9, 35.3) 1.2 (0.0, 2.7)
Marital status
Never married 68.6 (57.6, 79.6) 30.1 (19.9, 40.4) 1.2 (0.0, 2.1)
.085Married 67.7 (53.1, 82.3) 30.5 (17.7, 43.3) 1.7 (0.0, 3.7)
Others 60.0 (45.4, 74.5) 38.6  (25.5, 51.7) 1.4 (0.0, 3.7)
Employment status
Unemployed 65.5 (45.0, 86.1) 33.1 (14.1, 52.0) 1.4 (0.0, 3.0)
.579
Employed 68.2 (62.7, 73.7) 30.2 (25.9, 34.4) 1.6 (0.0, 3.2)
Total 66.94 (54.4, 79.5) 31.5 (20.4, 42.6) 1.5 (0.0, 3.0)
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Higher education (P < .0001) and monthly income (P = .009) 
were positively correlated with higher awareness. There 
was association between gender and awareness (P < .0001), 
age (P = .006), and marital status (P = .028) with outcome. 
Employment status (P = .888) showed no association with 
respondents’ awareness (Table 3).
Attitude
Opioid Use
95.5% (95% CI: 91.5, 99.5) of participants reported a negative 
attitude toward opioid use. Higher education was the only 
variable which was significantly correlated with attitude 
(P = .02) (Table 4). While 7.4% of respondents with low 
education reported a positive attitude, corresponding figure 
among graduated respondents was 1.2%. 
Stimulant Use
More than 96.0% (95% CI: 93.7, 99.5) of respondents had a 
negative attitude towards stimulants. Almost all of respondents 
(99.6, 95% CI: 98.5, 100) with a graduate degree reported a 
negative attitude regarding stimulants consumption. Negative 
attitude among less educated respondents was 95.1 (95% CI: 
92.8, 97.4; P = .05). Marital status was marginally associated 
with attitude (P = .06). Negative attitude in men and women 
were estimated at 97.1% and 96.2% respectively (P = .72). Age 
(P = .32), monthly income (P = .19) and employment status 
(P = .11) had no significant association with attitude toward 
stimulants use (Table 4).
Life Time Prevalence 
Opioid Use
The self-reported life time prevalence of opioid use was 
estimated at 12.9% (95% CI: 6.8, 19.0) (Table 5). Lifetime 
prevalence of opioid use was significantly higher in men 
than women — 21.5% (95% CI: 18.7, 24.3) versus 4.0% (95% 
CI: 1.9, 6.1). Prevalence in those aged >60 and 40-49 were 
20.9% (95% CI: 0.0, 43.4%), and 19.3% (95% CI: 8.8, 29.7) 
respectively. With respect to the marital status, the highest 
prevalence was estimated for whom categorized as “others,” 
including divorced, widows and separated (20.5, 95% CI: 
10.1, 30.9). Respondents with lowest education (19.8%, 95% 
CI: 5.0, 34.5) and who were employed (15.7% 95% CI: 9.7, 
21.8) reported highest lifetime prevalence of opioid use. With 
respect to income, highest prevalence was observed among 
middle lower incomes ($167-$334 per month) (Table 5).
Stimulant Use
Overall lifetime prevalence of stimulant use was estimated at 
7.3% (95% CI: 5.2, 9.4). Estimated prevalence for men was 
about 2 times that of women — 9.6% (95% CI: 6.1, 13.1) versus 
4.9% (95% CI: 0.7, 9.2). Among different age groups, the 
highest lifetime prevalence was observed among 20-29 years, 
12.0% (95% CI: 7.8, 16.2). As the respondents were getting 
older, the prevalence was sharply declined to 1.7 (95% CI: 
0.0, 5.3). With respect to marital status, those categorized as 
“others” reported the highest prevalence of lifetime stimulant 
use (13.6, 95% CI: 5.6, 21.6). Those with graduate degree 
were about 2 times higher than that of those with a degree 
below diploma (11.9 versus 6.5). Prevalence of stimulant use 
among those felt into highest monthly income category was 
noticeable (10.5, 95% CI: 7.0, 14.0) (Table 6).
Correlates of Lifetime Prevalence
Opioid Use 
Results of multivariable logistic regression modeling 
suggested that gender (AOR M/F = 6.92; 95% CI: 2.92, 16.41), 
Table 3. Awareness of Iranian Adults Towards Stimulant Use, 2015
Variable
Knowledge (%, 95% CI)
Good Moderate Weak P
Stimulants
Gender
Men 80.7 (71.4, 85.4) 15.6 (7.3, 17.8) 3.7 (1.2, 6.1)
<.0001
Women 82.2 (79.0, 85.4) 15.5 (13.1, 17.8) 2.3 (0.0, 4.6)
Education
Diploma or less 73.7 (68.1, 79.4) 21.2 (13.6, 28.7) 5.1 (2.3, 7.8)
<.0001Undergraduate 83.8 (76.9, 90.8) 13.8 (7.5, 20.0) 2.4 (0.0, 3.8)
Graduate 90.3 (85.1, 95.5) 9.2 (4.8, 13.8) 3.8 (0.0, 1.4)
Age
20-29 80.5 (75.1, 85.9) 16.7 (11.3, 22.0) 2.8 (1.6, 4.0)
.006
30-39 83.1 (77.6, 88.6) 12.9 (7.4, 18.4) 4.0 (0.0, 7.5)
40-49 79.5 (71.8, 87.0) 16.9 (11.3, 22.4) 3.7 (0.0, 7.2)
50-59 83.2 (77.2, 89.3) 15.6 (10.1, 21.0) 1.1 (0.0, 3.0)
More than 60 81.9 (58.2, 100) 16.8 (0.0, 41.4) 1.2 (0.0, 2.8)
Income
Less than 167 79.0 (76.0, 82.0) 15.7 (12.2, 19.2) 5.3 (2.8, 7.8)
.0009
167-334 81.5 (76.1, 86.9) 16.0 (12.0, 20.0) 2.5 (0.0, 4.6)
334-668 82.1 (72.2, 91.9) 17.0 (7.6, 26.4) 0.9 (0.0, 2.3)
More than 668 91.0 (82.5, 99.5) 8.5 (0.0, 16.5) 0.4 (0.0, 1.5)
Marital status
Never married 81.3 (74.7, 87.9) 15.8 (8.7, 22.9) 2.8 (1.4, 4.2)
0.028Married 82.8 (77.0, 88.6) 14.2 (9.3, 19.0) 3.0 (0.0, 6.2)
Others 76.7 (68.9, 84.4) 19.8 (9.8, 29.9) 3.4 (0.0, 6.5)
Employment status
Unemployed 81.4 (76.7, 86.2) 15.1 (10.8, 19.3) 3.5 (1.8, 5.1)
.888
Employed 81.4 (76.2, 86.7) 16.0 (10.7, 21.3) 2.5 (0.0, 4.9)
Total 81.4 (76.7, 86.2) 15.5 (11.2, 20.0) 3.0 (1.2, 4.8)
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Table 4. Attitude of Iranian Adults Towards Opioid and Stimulant Use, 2015
Variable
Opioids (n = 2065) Stimulants (n = 2065)
Negative Positive P Negative Positive P
Gender
Men 94.5 (88.4, 100) 5.5 (0.0, 11.6)
.55
97.1 (93.0, 100) 2.9 (0.0, 7.0)
.72
Women 96.6 (91.8, 100) 3.4 (0.0, 8.2) 96.2 (92.2, 100) 3.9 (0.0, 7.9)
Education
High school or less 92.6 (88.2, 97.0) 7.4 (3.0, 11.8)
.02
95. 1 (92.8, 7.4) 4.9 (2.6, 7.2)
.05Undergraduate 96.4 (93.0, 99.9) 3.6 (0.1, 7.0) 96.9 (93.8, 100) 3.1 (0.0, 6.2)
Graduated 98.8 (96.0, 100) 1.2 (0.0, 4.0) 99.6 (98.5, 100) 0.4 (0.0, 1.5)
Age
20-29 95.3 (0.9, 99.9) 4.7 (0.06, 9.3)
.37
96.0 (91.9, 100) 4.0 (0.0, 8.1)
.32
30-39 96.2 (0.9, 98.6) 3.8 (1.4, 6.3) 97.0 (94.8, 99.3) 3.0 (0.7, 5.2)
40-49 96.8 (91.3, 100) 3.2 (0.0, 8.7) 98.0 (95.4, 100) 2.0 (0.0, 4.6)
50-59 93.5 (87.7, 99.2) 6.6 (0.7, 12.3) 95.3 (91.3, 99.4) 4.7 (0.6, 8.8)
More than 60 93.9 (87.2, 100) 6.1 (0.0, 12.8) 96.8 (92.4, 100) 3.2 (0.0, 7.6)
Income
Less than 167 94.2 (89.7, 98.6) 5.8 (1.4, 10.3)
.16
95.8 (92.8, 98.9) 4.2 (1.2, 7.2)
.19
167-334 96.4 (92.7, 100) 3.6 (0.0, 7.2) 97.0 (93.8, 100) 3.1 (0.0, 6.2)
334-668 95.7 (92.3, 99.1) 4.3 (0.9, 7.7) 96.7(93.8, 99.5) 3.3 (0.5, 6.2)
More than 668 97.8 (92.9, 100) 2.2 (0.0, 7.1) 99.0 (96.5, 100) 1.0 (0.0, 3.5)
Marital status
Never married 96.0 (92.5, 99.5) 4.0 (0.5,7.5)
.6
97.1 (94.3, 99.9) 2.9 (0.1, 5.7)
.06Married 94.7 (90.3, 99.0) 5.3 (1.0, 9.7) 96.1 (93.2, 98.9) 3.9 (1.0, 6.8)
Others 97.4 (94.3, 100) 2.6 (0.0, 5.7) 97.5 (94.7, 100) 2.5 (0.0, 5.3)
Employment status
Unemployed 94.7 (90.3, 99.1) 5.3 (0.9, 9.7)
.24
95.6 (92.2, 99.0) 4.4 (1.0, 99.0)
.11
Employed 96.2 (92.3, 100) 3.8 (0.0, 7.7) 97.5 (94.8, 100) 2.5 (0.0, 5.2)
Total 95.5 (91.5, 99.5) 4.5 (0.5, 8.5) 96.6 (93.7, 99.5) 3.4 (0.5, 6.3)
Table 5. Lifetime Prevalence (95% CI) of Opioid Use Amongst Iranian Adults
Type of Drugs Variables Men (n = 1155) Women (n = 910) P Total (n = 2065)
Opioids
Age
20-29 17.2 (14.4, 19.9) 4.6 (2.1, 7.0) .038 10.8 (7.0, 14.6)
30-39 18.7 (7.3, 30.2) 3.8 (0.0, 7.6) .028 11.0 (4.8, 17.2)
40-49 30.7 (21.3, 40.1) 6.3 (2.2, 10.5) <.0001 19.3 (8.8, 29.7)
50-60 18.8 (15.0, 22.5) 0.8 (0.0, 2.7) .225 10.0 (2.8, 17.3)
60+ 32.4 (15.6, 49.1) - - 20.9 (0.0, 43.4)
Marital Status
Never Married 16.5 (12.8, 20.2) 3.7 (2.5, 5.0) .051 10.3 (5.9, 14.6)
Married 22.1 (19.2, 24.9) 2.4 (0.0, 6.4) .028 12.6 (5.4, 19.8)
Others 31.8 (27.5, 36.1) 10.0 (1.9, 18.1) <.0001 20.5 (10.1, 30.9)
Education
Diploma or Less 36.1 (29.2, 43.0) 2.5 (0.0, 6.0) .001 19.8 (5.0, 34.5)
Undergraduate 15.6 (13.5, 17.6) 5.3 (2.6, 7.9) .063 10.4 (7.9, 13.0)
Graduate 13.8 (11.4, 16.0) - - 7.5 (0.0, 17.4)
Income (US$)
Less than 167 23.1 (13.2, 33.0) 2.4 (0.0, 4.7) .023 9.5 (1.4, 17.7)
167-334 24.1 (19.8, 28.4) 7.5 (2.9, 12.0) .002 16.1 (11.1, 21.1)
334-668 20.6 (15.5, 25.7) 3.6 (0.0, 10.8) .018 15.2 (5.6, 24.7)
More than 668 14.6 (6.2, 23.0) 2.2 (0.0, 9.3) .123 11.3 (4.5, 18.1)
Employment status
Unemployed 21.2 (17.8, 24.7) 3.0 (1.3, 4.7) .023 9.8 (2.8, 16.9)
Employed 21.7 (17.7, 25.7) 5.5 (1.5, 9.4) .007 15.7 (9.7, 21.8)
Total 21.5 (18.7, 24.3) 4.0 (1.9, 6.1) .013 12.9 (6.8, 19.0)
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and marital status (AORothers/single = 2.13; 95% CI: 1.36, 3.33) 
were significantly correlated with lifetime prevalence of opioid 
use (Table 7). In addition, one level increase in education was 
associated with 60% decrease in odds of opioids use (P < .001).
Stimulant Use
One year increase in age was associated with 7% decrease in 
odds of stimulants use (P = .04). Marital status (AOROthers/singles 
= 3.45; 95% CI: 1.09, 10.93), and awareness (AORWeak and moderate/
good = 0.40; 95% CI: 0.25, 0.60) had independent correlation 
with life time prevalence of stimulants use (Table 8).
Discussion
A large cross-sectional study in 5 major cities of Iran was 
performed to estimate population-based statistics on the 
awareness, attitudes towards opioid and stimulant use and 
their lifetime prevalence. This study reflected that participants 
had a good level of awareness of opioid (67%) and stimulant 
use (82%) and almost all of the respondents had negative 
attitudes toward the drugs. Lifetime prevalence of opioid and 
stimulant use was 12.9% and 7.2%, respectively.
Good level of awareness observed among Iranian adults in 
general population was higher than corresponding figures 
among Iranian students34,35; which may be due to lack of 
comprehensive and mandatory course in educational system, 
though lower awareness is expected among youths. Moreover, 
a most recent population-based study on Iranian youths (19-
29 years) showed that 42% of them had good knowledge on 
methamphetamine, which is lower than our findings. We 
should mention that our questioner was not the same as 
that used in study.24 While we covered all types of stimulants 
and drugs, they only asked about methamphetamines in 
details. Some other evidences, related to pre-epidemic phase 
of stimulants use in Iran, reflected very low knowledge 
among students(1%-2%).36,37 Amphetamine epidemic in Iran 
happened during 2005-2008 when domestic production of 
glass was burgeoned. During the epidemic mass media and 
newspapers abundantly provided documentaries, video clips 
and articles about adverse effects of stimulant use, therefore, 
in parallel these have formed negative attitude toward 
stimulants use.14,38
On the other hand, limited evidence on awareness about 
opioids among Iranian adults is available. Being on the main 
route of drug trafficking, from Western Asia to Eastern Europe, 
as well as cultural issues (medical and recreational uses) and 
relatively low cost, provoke Iranian to use opioids. In contrast 
having good knowledge about opioid use, colonialism of the 
Great Britain on Iran opioid market caused negative attitude 
toward opioid use.39,40
While men were more likely to use opioids and stimulants, 
no association between gender and attitude toward opioids 
and stimulants use was found. This might be partially justified 
by previous evidences which suggested that a considerable 
proportion of people use in their life course drugs before the 
formation of negative attitudes.41
Lifetime prevalence of opioid use reported about 17% in 
the Northern and southeastern of Iran (ever users), which are 
known as hot zones and high prevalent areas.42,43 Estimation 
Table 6. Lifetime Prevalence (95% CI) of Stimulants Use Amongst Iranian Adults
Type of Drugs Variables Men (n = 1155) Women (n = 910) P Total (n = 2065)
Stimulants
Age
20-29 14.7 (11.4, 18.1) 9.4 (0.0, 18.8) .233 12.0 (7.8, 16.2)
30-39 8.7 (7.2, 10.1) 3.2 (1.1, 5.4) .322 5.9 (4.3, 7.4)
40-49 8.1 (4.6, 11.6) 2.3 (0.0, 4.6) .349 5.3 (3.2, 7.5)
50-60 3.2 (0.0, 9.2) 0.4 (0.0, 1.7) .755 1.9 (0.0, 4.7)
60+ 2.7 (0.0, 8.6) - - 1.7 (0.0, 5.3)
Marital Status
Never Married 13.6 (10.0, 17.1) 4.8 (2.5, 7.2) .109 9.3 (7.6, 10.9)
Married 5.8 (1.8, 9.8) 2.8 (0.0, 5.0) .558 4.4 (2.1, 6.6)
Others 14.5 (3.3, 25.6) 12.8 (0.0, 25.8) .684 13.6 (5.6, 21.6)
Education
Diploma or Less 12.2 (6.6, 17.8) 0.4 (0.0, 1.0) .473 6.5 (1.2, 11.8)
Undergraduate 7.5 (3.8, 11.2) 6.5 (1.9, 11.1) .818 7.0 (4.3, 9.7)
Graduate 14.3 (11.6, 17.0) 9.0 (4.5, 13.4) .237 11.9 (7.3, 16.3)
Income (US$)
Less than 167 15.9 (12.2, 19.6) 2.7 (0.0, 5.5) .077 7.2 (2.9, 11.6)
167-334 7.8 (1.2, 14.1) 8.5 (2.6, 14.5) .869 8.1 (3.4, 12.7)
334-668 5.5 (2.0, 9.0) 5.8 (3.2, 8.4) .944 5.6 (3.0, 8.2)
More than 668 12.1 (6.5, 17.7) 6.0 (3.2, 8.8) .210 10.5 (7.0, 14.0)
Employment status
Unemployed 11.1 (6.0, 16.3) 4.8 (0.0, 10.3) .220 7.2 (3.4, 10.9)
Employed 8.7 (5.9, 11.6) 5.2 (3.0, 7.3) .456 7.4 (6.1, 8.8)
Total 9.6 (6.1, 13.1) 4.9 (0.7, 9.2) .335 7.3 (5.2, 9.4)
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of prevalence of opioid use in specific populations was of 
great attention. Exploring drug use among high school 
students indicated wide variation of experiencing opioids, 
1.2% to 8.6%.22 Some specific populations such as drivers and 
prisoners were categorized as high risk groups of opioid use, 
with prevalence ranged 26.5% to 79%.44,45 As opioids are the 
most prevalent drug in Iran8, appropriate strategies and harm 
reduction programs should be designed to decrease its burden 
and adverse side effects such as hepatitis C and HIV/AIDS.
Though stimulants marketing is relatively new in Iran, its 
life time prevalence among those aged 19-29 was estimated 
at 6%.24 Results of a similar study in Tehran confirmed our 
results.46 The lifetime prevalence of stimulants varied among 
subpopulations, less than 1% among women to more than 
13% among body builders.47
We have seen remarkable gender difference in terms of 
opioids and stimulants use. This finding was in line with 
others results. It is known that men are more likely to show 
high risk behaviors than women, in particular in Iran due to 
cultural background.22,46,48 Moreover, it has been indicated 
that men usually transit to drug use from cigarette smoking 
– prevalence of daily smoking among men is about 24% in 
Iran – while women initiates with opium.49 Despite lower 
prevalence of opioid use among women, they need specific 
harm reduction programs because women often provide 
sexual intercourse in exchange for money or drug. This in 
turn increases sexual transmitted infections such as HIV/
AIDS.50
As it had reported in previous works,9,51 more educated 
respondents were less likely to use opioids. It may not be 
considered as a result of higher awareness or more negative 
attitude as these were not remained into the final multivariable 
model.
Those who formed that category “divorced or widow or 
separated” reported significant higher lifetime prevalence of 
both of opioid and stimulant use. This population is more 
likely to have high risk behaviors as compared with single 
and married populations, partially because of mental distress 
which is one of the most important reason for initiating 
drugs.52,53 As the number of divorced or separated peoples has 
been increasing in recent years,54 it may be the future concern 
of the public health in Iran.
Table 7. Determinants of Opioid Use in Iran
Type of Drugs Variables Crude OR (95% CI) P Adjusted OR (95%CI) P
Opioids
Age
20-29 Reference
30-39 1.02 (0.58, 1.81) .928 0.97 (0.46, 2.03) .931
40-49 1.97 (1.39, 2.79) .002 1.07 (1.70, 2.89) .037
50-59 0.92 (0.51, 1.66) .762 0.88 (0.49, 1.59) .629
60+ 2.19 (0.72, 6.60) .141 1.39 (0.45, 4.24) .519
Gender
Men Reference
Women 6.58 (3.74, 11.59) <.0001 6.92 (2.92, 16.42) <.0001
Education 
Diploma or less Reference
Undergraduate 0.47 (0.22, 1.00) .051 0.49 (0.26, 0.90) .027
Graduate 0.33 (0.10, 1.04) .057 0.31 (0.23, 0.41) <.001
Marital status
Single Reference
Married 1.26 (0.79, 2,00) .282 1.06 (0.79, 1.42) .663
Others 2.25 (1.42, 3.60) .004 2.13 (1.36, 3.33)  .004
Income
Less than 167 Reference
167-334 1.82 (0.72, 4.62) .174 1.34 (0.54, 3.29) .760
334-668 1.70 (0.63, 4.58) 1.230 1.10 (0.63, 1.91) .400
More than 668 1.21 (0.53, 2.74) .550 0.68 (0.26, 1.78) .382
Employment status
Unemployed Reference
Employed 1.71 (0.90, 3.24) .089 1.22 (0.73, 2.04) .394
Attitudes
Negative Reference
Positive 1.85 (0.57, 6.02) .263 1.52 (0.58, 3.99) .347
Awareness
Good Reference
Weak 0.62 (0.21, 1.84) .341 0.61(0.88, 4.23) .574
Moderate 0.30 (0.06, 1.40) .109 0.34 (0.03, 4.00) .341
Abbreviation: OR, odds ratio.
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Limitations
We were not able to estimate current prevalence of opioids 
and stimulants use; as questions about recent use is more 
sensitive.
We should also mention that we used direct question to 
estimate prevalence. It has been shown that direct questions 
prone to prestige biases and might provide an under-estimated 
prevalence. We already applied indirect methods such as NSU 
among general population. In NSU, respondents describe 
their network in terms of drug use. Therefore, prestige bias is 
of less concern. Instead recall bias and invisibility of hidden 
characteristics might provide inaccurate estimates. 
As no standardized instrument was available, we used a 
researcher-developed instrument to measure awareness, 
attitude and life time prevalence. However, this limitation is 
pervasive in this field in Iran. Therefore, development of a 
standardized questionnaire for such studies on the drug use 
would be helpful for future works.
One more limitation of our study was that we were not able 
to conduct a household survey. We approached pedestrians 
in the street. Therefore, our sample was not a random sample 
of the general population. However, our previous experiences 
suggested that street-based sampling was the optimum 
approach in the case of sensitive characteristics in Iran.55,56
Conclusion
Despite negative attitudes of Iranian adults toward opioid 
and stimulant use, their awareness was less adequate to 
prevent high risk behavior. Men and participants with lower 
socio-economic status (SES) should be considered as a main 
target population of health promotion programs for opioid 
use. However, regarding stimulants use, health promotion 
programs which focused mostly on youths and who had higher 
SES could be more effective. Considering wide distribution 
of virtual world and increasing trend of internet access, we 
suggest that future studies work on sharing info-graphs of 
illicit drug use side effects and also assessing educational 
packages on the network, which could be the fastest, easiest, 
and most cost-effective way of informing the society. Iran 
education curriculum needs to be revised in which drug use 
should be included. In addition, parent should be trained 
periodically to recognize high-risk behavior warning signs in 
Table 8. Determinants of Stimulants Use in Iran
Type of Drugs Variables Crude OR (95% CI) P Adjusted OR (95%CI) P
Stimulants
Age
20-29 Reference
30-39 0.46 (0.31, 0.68) .002 0.44 (0.22, 0.89) .027
40-49 0.41 (0.25, 0.68) .004 0.32 (0.14, 0.75) .015
50-59 0.14 (0.03, 0.73) .025 0.11 (0.01, 0.88) .040
60+ 0.13 (0.01, 1.09) .058 0.08 (0.01, 0.98) .049
Gender
Men Reference
Women 2.03 (0.76, 5.44) .136 2.15 (0.83, 5.56) .099
Education 
Diploma or less Reference
Undergraduate 1.10 (0.42, 2.86) .220 0.75 (0.35, 1.61) .410
Graduate 1.95 (0.68, 5.56) .180 1.51 (0.73, 3.11) .219
Marital status
Single Reference
Married 0.44 (0.25, 0.78) .011 0.86 (0.44, 1.71) .632
Others 1.54 (0.70, 3.40) .245 1.69 (1.10, 10.72) .037
Income
Less than 167 Reference
167-334 1.13 (0.39, 3.27) .797 1.38 (0.51, 3.76) .481
334-668 0.76 (0.31, 1.89) .512 1.42 (0.62, 3.23) .356
More than 668 1.50 (0.71, 3.17) .242 2.00 (1.32, 3.01) .005
Employment status
Unemployed Reference
Employed 1.04 (0.60, 1.78) .877 0.65 (0.41, 1.00) .052
Attitudes
Negative Reference
Positive 1.71 (0.63, 4.61) .249 1.51 (0.70, 3.23) .252
Awareness
Good Reference
Weak 0.30 (0.10, 0.85) .029 0.35 (0.15, 0.60) .007
Moderate 0.15 (0.04, 0.50) .007 0.45 (0.12, 0.83) .019
Abbreviation: OR, odds ratio.
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children and adolescents. Further investigations are needed 
to identify appropriate and effective approaches based on 
Iranian socio-cultural context that benefit the population 
with available resources.
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